Disse data bekræftede, at fordelene ved Xigris er begrænset til de hårdest ramte sepsispatienter såsom patienter med multiorgandysfunktion eller shock.
These data confirmed that the benefit of Xigris is limited to the more severely affected sepsis patients such as patients with multiple organ failure and shock.